Germline <i>TP53 </i>Testing in Breast Cancers: Why, When and How?

by D. Gareth Evans, Emma R. Woodward, Svetlana Bajalica-Lagercrantz, Carla Oliveira, Thierry Frebourg
Published 2020-12-01

Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53

by Meis Omran, Lennart Blomqvist, Yvonne Brandberg, Niklas Pal, Per Kogner, Anne Kinhult Ståhlbom, Emma Tham, Svetlana Bajalica-Lagercrantz
Published 2020-01-01

Association between Predicted Effects of <i>TP53</i> Missense Variants on Protein Conformation and Their Phenotypic Presentation as Li-Fraumeni Syndrome or Hereditary Breast Cancer

by Yaxuan Liu, Olga Axell, Tom van Leeuwen, Robert Konrat, Pedram Kharaziha, Catharina Larsson, Anthony P. H. Wright, Svetlana Bajalica-Lagercrantz
Published 2021-06-01

Expression of the p53 target Wig-1 is associated with HPV status and patient survival in cervical carcinoma.

by Li-Di Xu, Susanne Muller, Srinivasan R Thoppe, Fredrik Hellborg, Lena Kanter, Mikael Lerner, Biying Zheng, Svetlana Bajalica Lagercrantz, Dan Grandér, Keng Ling Wallin, Klas G Wiman, Catharina Larsson, Sonia Andersson
Published 2014-01-01